Journal of Addiction Medicine最新文献

{"title":"Xylazine Use in Pregnancy: A Case Report and Narrative Review.","authors":"Kaitlyn Kasemodel, Spencer Ilstrup, Jaymie Avenido, Alan Lynch, Robert Castiglia, Dexter Reneer","doi":"10.1097/ADM.0000000000001641","DOIUrl":"10.1097/ADM.0000000000001641","url":null,"abstract":"<p><p>Xylazine, an alpha-2 adrenergic agonist veterinary sedative, has emerged as a frequent adulterant in illicit opioids, contributing to the ongoing \"tranq dope\" crisis. Its effects on human pregnancy are largely unknown, posing new challenges in obstetric addiction medicine. We present the case of a 25-year-old woman (G4P2113) with opioid use disorder who unknowingly used fentanyl adulterated with xylazine throughout pregnancy. She developed preeclampsia with HELLP syndrome, requiring urgent preterm cesarean delivery at 34 weeks. The neonate was treated for neonatal abstinence syndrome. Four days postpartum, the patient-discharged without medication for opioid use disorder-suffered intractable vomiting from withdrawal, leading to a Mallory-Weiss tear with massive hemorrhage and cardiac arrest. She required intensive care with transfusions, endoscopic hemostasis, and mechanical ventilation. Upon extubation, she disclosed fentanyl-xylazine (\"tranq\") use. She was transitioned to buprenorphine maintenance with supportive care for xylazine withdrawal and discharged in improved condition. We review the sparse human literature on xylazine exposure in pregnancy and relevant animal studies. Human data confirm placental transfer of xylazine, with umbilical cord assays detecting exposure, and suggest that xylazine may contribute to maternal CNS depression and neonatal sedation. Animal models demonstrate dose-dependent uterine vasoconstriction, reduced uteroplacental blood flow, fetal growth restriction, and pregnancy loss. We discuss management considerations for pregnant patients using xylazine-adulterated opioids, including challenges in diagnosis, withdrawal management, and the need for expanded harm-reduction strategies. This case and review highlight the urgent need for surveillance and evidence-based protocols to address xylazine in the perinatal setting.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"e16-e21"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylphenidate for the Treatment of Cocaine Use Disorder: A Systematic Review and Meta-analysis.","authors":"Letizia Biso, Marianna Lebosi, Marco Bonaso, Marco Carli, Marco Scarselli","doi":"10.1097/ADM.0000000000001599","DOIUrl":"10.1097/ADM.0000000000001599","url":null,"abstract":"<p><strong>Objectives: </strong>Cocaine use disorder (CUD) is a chronic condition, often associated with attention deficit hyperactivity disorder (ADHD). No medications have been approved for the treatment of CUD, but methylphenidate (MPH) has been explored as a potential candidate. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of MPH in patients with CUD with and without ADHD.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we developed a search string for PubMed, ISI Web of Science, and Scopus databases. We included randomized and nonrandomized clinical studies that used MPH in CUD treatment.</p><p><strong>Results: </strong>Twenty studies were included in the systematic review, 6 of them were included in the meta-analysis. In the meta-analysis, MPH did not reduce craving (ES: -0.33, 95% CI: 1.69 to 1.03; Z = -0.473; P = 0.636) or cocaine use (ES: -0.01, 95% CI: -0.35 to 0.33) (Z= -0.084; P = 0.933) compared with placebo. However, the route of administration and the presence of ADHD associated with CUD influenced the outcomes on cocaine craving measures. Similarly, although the results were inconclusive, a trend toward the reduction of cocaine consumption was observed in patients with ADHD treated with MPH. Regarding safety, MPH can be used in patients with CUD up to 90 mg/d and monitoring the cardiovascular parameters is strictly required.</p><p><strong>Conclusions: </strong>Evidence on the efficacy of MPH for the treatment of CUD is still limited and inconclusive. However, there might be a rationale for its use in patients with both CUD and ADHD, therefore, further clinical studies are needed in this particular category.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"619-625"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing the Efficacy of an Adaptive Approach to Delivering Psychosocial Interventions in Office-based Buprenorphine Treatment.","authors":"Karen L Dugosh, S Brook Burkley, James R McKay, Kyle M Kampman, Kevin G Lynch, Michelle R Lent","doi":"10.1097/ADM.0000000000001643","DOIUrl":"10.1097/ADM.0000000000001643","url":null,"abstract":"<p><strong>Objectives: </strong>Clinical guidelines recommend providing adjunctive psychosocial interventions with medications for opioid use disorder (MOUD); however, limited evidence exists regarding when and how to provide them. This 2-group unblinded randomized controlled trial evaluated the efficacy of an adaptive approach to providing cognitive behavioral therapy and peer support for individuals receiving office-based buprenorphine treatment.</p><p><strong>Methods: </strong>Between September 2020 and May 2023, 125 patients who recently initiated office-based buprenorphine treatment at 2 federally qualified health centers in the Mid-Atlantic region and provided informed consent were randomly assigned (1:1) to treatment as usual (TAU; n = 63) or TAU plus adjunctive psychosocial treatment delivered using an adaptive algorithm informed by baseline characteristics, engagement, and responsiveness (TAU+Adaptive; n = 62). Assessments occurred at baseline and 3- and 6-month follow-ups. Primary outcomes were treatment retention and opioid use.</p><p><strong>Results: </strong>No significant between-group differences were observed. Across conditions, about 30% tested positive for opioids at follow-up, and 40% remained in MOUD treatment at 6 months. Exploratory post hoc analyses indicated greater retention among participants prescribed a 24 mg baseline buprenorphine dose (46%) compared with those on 16 (24%) or 8 mg (26%). No serious study-related adverse events were reported.</p><p><strong>Conclusions: </strong>Although the efficacy of the adaptive approach was not supported, high rates of treatment discontinuation and polysubstance use highlight the need for additional support for some patients. Findings also suggest that dosing strategies may need to be tailored to the increasing potency of the illicit opioid supply.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"567-574"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Wounds and Association With Xylazine Using Respondent-driven Sampling Among People Who Inject Drugs in Baltimore, Maryland.","authors":"Andrea N Ponce, Danielle German, Mollie M A McMahon, Kim Ashburn, Allison McFall, Becky L Genberg","doi":"10.1097/ADM.0000000000001755","DOIUrl":"10.1097/ADM.0000000000001755","url":null,"abstract":"<p><strong>Objectives: </strong>To estimate the population-level prevalence of wounds and their association with xylazine use and other correlates, characterize wound features, and describe wound care experiences.</p><p><strong>Methods: </strong>Cross-sectional study in Baltimore, Maryland, between April and July 2024. Participants at least 18 years old, who resided in the Baltimore metropolitan area, and self-reported injecting drugs in the past year were recruited using respondent-driven sampling (RDS). Wound outcomes were self-reported history of any wound and xylazine-attributed wounds. Population proportions were generated using the RDS-II estimator. Robust Poisson regression with sampling weights was used to assess correlates of any wound history.</p><p><strong>Results: </strong>Among 315 participants, 39.4% had any wound history, of which 80.1% attributed at least 1 wound to xylazine. Homelessness, unemployment, and past 3-month nonmedical use of fentanyl, benzodiazepine, methamphetamine, and xylazine with other drugs were associated with higher wound prevalence. Those who experienced xylazine-attributed wounds (n=89) reported a small blister or bump (59.6%), necrotic eschar (52.8%), or necrotic slough (51.7%) and wounds at the injection site (61.8%). Health care-seeking behaviors were mixed, with participants reporting both seeking and avoiding or delaying care for xylazine-attributed wounds.</p><p><strong>Conclusions: </strong>These population-based estimates indicate a substantial burden of wounds among people who inject drugs in the Baltimore metropolitan area in 2024. More research is needed to strengthen the evidence base for xylazine-associated wounds to inform policy and clinical decision-making. Expanded training in wound progression and basic wound care will better prepare the health care and harm reduction workforce to manage wounds.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"e22-e30"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Whatever it is, it Works\" Understanding of Buprenorphine/Naloxone and Sources of Information: A Qualitative Study Among People Who Use Fentanyl and Clinicians.","authors":"Olivia L Gregorich, Judith I Tsui, Geetanjali Chander, Jessica S Merlin, Elenore P Bhatraju","doi":"10.1097/ADM.0000000000001652","DOIUrl":"10.1097/ADM.0000000000001652","url":null,"abstract":"<p><strong>Objectives: </strong>Most persons with opioid use disorder (OUD) are not receiving effective treatment with medications. A lack of understanding and misinformation may impede an individual's decision to begin or continue medications for OUD (MOUD). This study explored the understanding of the role of naloxone, and sources of information related to buprenorphine/naloxone products among people who use fentanyl (PWUF) and clinicians.</p><p><strong>Methods: </strong>Qualitative study utilizing semi-structured interviews with PWUF and clinicians providing buprenorphine care. Participants were recruited via flyers and word of mouth (PWUF), and direct emails (clinicians). Interviews were audio recorded, transcribed, and analyzed using a rapid qualitative analysis process, which consists of creating templated summaries separated by domains to formulate themes.</p><p><strong>Results: </strong>Forty-three adults (28 PWUF and 15 clinicians) from Seattle, WA, participated in interviews between April and November 2024. The analyses identified 3 themes: (1) PWUF and clinicians both acknowledge confusion around how buprenorphine and naloxone work; (2) misconceptions may lead to adverse events, anxiety, and/or lack of interest in starting buprenorphine, especially in the setting of fentanyl use; (3) while PWUF had high regards for clinicians, the primary and most trusted source of information is people with lived experience taking buprenorphine/naloxone.</p><p><strong>Conclusions: </strong>Findings suggest confusion and lack of information about the role of naloxone in buprenorphine/naloxone, potentially limiting medication uptake. The finding that patients mainly hear about buprenorphine/naloxone from people with lived experience should be incorporated into outreach strategies. Future efforts should increase involvement from people with lived experience taking buprenorphine in disseminating accurate information regarding MOUD.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"532-537"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benzodiazepine Tapering: A Marathon, Not a Sprint.","authors":"Yngvild Olsen, Emily Brunner, Chinyere Ogbonna, Maureen P Boyle","doi":"10.1097/ADM.0000000000001657","DOIUrl":"10.1097/ADM.0000000000001657","url":null,"abstract":"<p><p>Clinicians have prescribed benzodiazepines for a range of symptoms and conditions since the Food and Drug Administration approved chlordiazepoxide in 1960. Between 1969 and 1982, the benzodiazepine diazepam was the most prescribed medication in the United States. Since then, recognition of benzodiazepine's risks-such as falls, psychomotor and cognitive impairment, withdrawal, benzodiazepine use disorder (BzUD), and suicidality-and limited data on long-term safety and efficacy have created challenges for clinicians and patients, including when and how to safely taper these medications. In 2025, 10 professional societies, including the American Society of Addiction Medicine (ASAM), released the Joint Clinical Practice Guideline on Benzodiazepine Tapering. This commentary explores implications for addiction treatment.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"522-524"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Interventions for Electronic Cigarette Cessation: A Systematic Review and Meta-analyses.","authors":"Ailifeire Aihemaiti, Ying Xie, Zheng Su, Xinmei Zhou, Zhao Liu, Anqi Cheng, Zhenxiao Huang, Liang Zhao, Dan Xiao, Chen Wang","doi":"10.1097/ADM.0000000000001631","DOIUrl":"10.1097/ADM.0000000000001631","url":null,"abstract":"<p><strong>Objectives: </strong>The rising global prevalence of electronic cigarette (e-cigarette) use poses significant public health concerns, including nicotine dependence. This systematic review and meta-analysis evaluated the efficacy and safety of pharmacological interventions for e-cigarette cessation.</p><p><strong>Methods: </strong>We systematically searched 5 databases, including Cochrane Library, PubMed, Ovid Embase, Sinomed, and Web of Science Core Collection, up to May 1, 2024, that evaluated the efficacy and safety of pharmacological intervention compared with placebo for e-cigarette cessation. Two investigators independently screened studies, extracted data, and assessed the risk of bias. The outcomes of interest were (1) continuous abstinence rate (CAR); (2) 7-day point prevalence of e-cigarette abstinence at different weeks; and (3) adverse effects. This study was registered with PROSPERO (CRD42024577356).</p><p><strong>Results: </strong>Of 1567 initially identified records, 7 studies involving 1161 participants were included. Most studies had a low risk of bias. The results indicated that varenicline (4 studies, n=463; OR=2.52, 95% CI: 1.14-5.58) was effective, while the effect of nicotine replacement therapy (NRT; 2 studies, n=538; OR=1.38, 95% CI: 0.61-3.14) was not statistically significant. One study on cytisine also suggested potential benefit.</p><p><strong>Conclusions: </strong>Varenicline has demonstrated efficacy in supporting e-cigarette cessation, whereas the current evidence for NRT and cytisine remains insufficient to draw firm conclusions. Further well-designed studies are needed to clarify the effectiveness of these 2 interventions. Although pharmacotherapies used for cigarette smoking show potential for repurposing, their utility in e-cigarette cessation should be interpreted cautiously until stronger evidence becomes available.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"556-566"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Correlates of Past-year Kratom Use Among US Adults: Findings From the 2021-2023 National Survey on Drug Use and Health.","authors":"Chung Jung Mun, Patricia Timmons, Manuel Cano","doi":"10.1097/ADM.0000000000001637","DOIUrl":"10.1097/ADM.0000000000001637","url":null,"abstract":"<p><strong>Objectives: </strong>Kratom is now widely available in the United States, yet epidemiological data remain sparse. This study examined the prevalence and correlates of kratom use among adults in the civilian noninstitutionalized US population using the most recent National Survey on Drug Use and Health (NSDUH) data.</p><p><strong>Methods: </strong>Data from the 2021-2023 NSDUH were limited to adults aged 18+ years (n = 139,524). Weighted prevalence estimates were calculated overall, by year, and by demographic and clinical characteristics. Logistic regression models were used to examine correlates of past-year kratom use.</p><p><strong>Results: </strong>The combined (2021-2023) weighted prevalence of past-year kratom use among US adults was 0.68% (95% CI, 0.60%-0.77%), remaining stable across survey years. Kratom use was more common among males, adults aged 26-49, and non-Hispanic white or multiracial adults. Prevalence exceeded 2% among adults reporting serious psychological distress or a major depressive episode, and exceeded 5% among those reporting certain types of substance use or prescription medication misuse. In covariate-adjusted analyses, higher odds of kratom use were observed among men, adults aged 35-49 years, and those reporting prescription pain reliever use or misuse, as well as cigarette, cannabis, and ketamine use, whereas lower odds were observed among black and Hispanic adults compared with white adults.</p><p><strong>Conclusions: </strong>Kratom use among adults in the United States was relatively stable between years 2021 and 2023 and concentrated among individuals with reported psychological distress and substance use. Future studies should include more comprehensive assessments of kratom use, and screening for kratom use in high-risk clinical populations may be warranted.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"538-547"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Emergency Department Distribution of Fentanyl Test Strips.","authors":"Marina Gaeta Gazzola, Chelsea Hayman, Danielle Wright, Jung G Kim, Nicholas Genes, Ian Wittman, Kelly M Doran, Christian Koziatek, Yelan Wang, Silas W Smith, Dowin H Boatright","doi":"10.1097/ADM.0000000000001651","DOIUrl":"10.1097/ADM.0000000000001651","url":null,"abstract":"<p><strong>Objectives: </strong>Fentanyl test strips (FTS) have the potential to moderate drug use behavior amidst an unregulated drug supply, yet are underutilized in medical settings. We aimed to describe emergency department (ED) FTS distribution across a large NYC health system and examine characteristics associated with clinicians' ordering FTS compared with the current standard-of-care, take-home naloxone (THN), to identify opportunities to optimize FTS distribution.</p><p><strong>Methods: </strong>We conducted a retrospective review of THN and FTS provision across a large urban health system in its first year of FTS distribution. We evaluated the demographic and clinical characteristics of visits in which clinicians ordered FTS, compared with THN only.</p><p><strong>Results: </strong>From July 20, 2022 to July 20, 2023, 237 (of 423) clinicians ordered THN for 1279 unique individuals in 1376 eligible visits (436 with FTS, 940 without). In pairwise analysis, FTS receipt was associated with being male, younger, non-White, lacking commercial insurance; substance-related or overdose-related visit chief complaint or diagnosis, attending physician, and patient-directed discharge ( P <0.05 for each). In multivariable regression, higher odds of FTS receipt were associated with male gender (OR=2.4; 95% CI=1.8-3.5), a substance-related chief complaint (OR=2.0; 95% CI=1.2-3.2) or visit diagnosis (OR=5.5; 95% CI=3.8-8.0), and overdose visit diagnosis (OR=1.7; 95% CI=1.1-2.8). Lower odds of FTS receipt were associated with older age (OR=0.98; 95% CI=0.97-0.99), noncommunity hospital sites (OR=0.71; 95% CI=0.60-0.83), and non-attending clinicians (OR=0.83; 95% CI=0.69-0.98).</p><p><strong>Conclusions: </strong>Integrating FTS into an existing ED THN program was feasible without disrupting clinical workflow. ED encounters where FTS were dispensed differed significantly from THN-only, revealing opportunities to optimize FTS ordering.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"e57-e63"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Alcohol Use and Self-reported Pain: Insights From the 2020 National Health Interview Survey.","authors":"Ling Liu, Nasim Maleki","doi":"10.1097/ADM.0000000000001598","DOIUrl":"10.1097/ADM.0000000000001598","url":null,"abstract":"<p><strong>Objectives: </strong>Alcohol use and pain are both prevalent public health concerns, yet their associations at the population level remain understudied. This study examines the relationship between alcohol consumption and self-reported pain among US adults.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted using data from the 2020 National Health Interview Survey, a nationally representative data set by the National Center for Health Statistics. The analytic sample included 24,499 adults aged ≥18 years (mean age=51.6, SD=18.0). Alcohol consumption in the past 12 months was categorized as nondrinking (<1 drink ever), light (≤3 drinks/wk), moderate (males: 4-14; females: 4-7 drinks/wk), and heavy (males: >14; females: >7 drinks/wk) drinking. Pain (acute or chronic) frequency, severity, and interference over the past 3 months were assessed via self-report. Adjusted logistic regression models were used to estimate associations.</p><p><strong>Results: </strong>A dose-response relationship was observed: compared with nondrinkers, odds of experiencing pain were higher among heavy drinkers (aOR=1.76; 95% CI: 1.30-2.37), moderate (aOR=1.39; 95% CI: 1.10-1.76), and light (aOR=1.32; 95% CI: 1.10-1.60). Our analyses further revealed that while pain frequency and severity were significantly associated with the severity of alcohol use, pain-related interference with daily life and family functioning did not differ significantly by drinking status. Opioid use was also more common among moderate and heavy drinkers.</p><p><strong>Conclusions: </strong>Higher alcohol consumption is significantly associated with increased likelihood of pain, with a clear dose-response pattern. Findings underscore the need for integrated screening and intervention targeting both alcohol use and pain.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"610-618"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}